73 results
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
18 Dec 23
Third party tender offer statement (amended)
6:59am
diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
4 Dec 23
Third party tender offer statement (amended)
7:04am
care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
17 Nov 23
Third party tender offer statement (amended)
6:53am
care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions
SC TO-T/A
EX-99
LLY
Lilly(Eli) & Co
15 Nov 23
Third party tender offer statement (amended)
6:51am
diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing
SC TO-T/A
EX-99
s8to6cxx2kwe
8 Nov 23
Third party tender offer statement (amended)
5:06pm
SC TO-T
EX-99
4gdv6h2s fzo3ui8svn
13 Oct 23
Third party tender offer statement
6:52am
SC14D9C
EX-99.2
fbizv
3 Oct 23
Written communication relating to third party tender offer
5:24pm
SC TO-C
EX-99.1
vhefc mfo
3 Oct 23
Information about tender offer
4:30pm
SC14D9C
EX-99.4
00r4 hn379h883m0
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
EX-99.4
gwlqs 6utiot
3 Oct 23
Tender and Support Agreement
7:35am
ARS
rovlg9e4qs1
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-1.1
mrr4n3 eznyrkdyz
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
8-K
EX-99.2
wdxd1rnt
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am